Coherus BioSciences, Inc. (NASDAQ:CHRS) shares traded up 22.1% during trading on Monday . The stock traded as high as $13.80 and last traded at $13.55, with a volume of 1,337,530 shares changing hands. The stock had previously closed at $11.10.

Several research analysts have recently commented on the stock. Cowen and Company reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Coherus BioSciences in a report on Tuesday, June 13th. Citigroup Inc. decreased their price target on shares of Coherus BioSciences from $38.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, June 13th. Robert W. Baird decreased their price target on shares of Coherus BioSciences from $40.00 to $37.00 and set an “outperform” rating for the company in a report on Tuesday, June 13th. BMO Capital Markets assumed coverage on shares of Coherus BioSciences in a report on Friday, May 5th. They issued an “outperform” rating and a $54.00 price target for the company. Finally, Maxim Group decreased their price target on shares of Coherus BioSciences from $44.00 to $40.00 and set a “buy” rating for the company in a report on Monday, June 12th. Two research analysts have rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. Coherus BioSciences currently has an average rating of “Buy” and an average price target of $34.70.

The stock’s market cap is $708.57 million. The firm’s 50 day moving average is $13.06 and its 200 day moving average is $18.81.

Coherus BioSciences (NASDAQ:CHRS) last released its earnings results on Monday, August 7th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.29) by $0.21. Coherus BioSciences had a negative return on equity of 307.41% and a negative net margin of 73.89%. The firm had revenue of $1.40 million for the quarter. Analysts predict that Coherus BioSciences, Inc. will post ($5.13) earnings per share for the current year.

In other Coherus BioSciences news, insider Alan C. Herman sold 17,535 shares of Coherus BioSciences stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $15.02, for a total value of $263,375.70. Following the transaction, the insider now owns 49,651 shares in the company, valued at $745,758.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 32.88% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CHRS. California State Teachers Retirement System boosted its stake in Coherus BioSciences by 2.3% in the second quarter. California State Teachers Retirement System now owns 67,940 shares of the biotechnology company’s stock valued at $975,000 after buying an additional 1,500 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Coherus BioSciences by 26.3% in the second quarter. The Manufacturers Life Insurance Company now owns 30,393 shares of the biotechnology company’s stock valued at $436,000 after buying an additional 6,327 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Coherus BioSciences during the second quarter valued at $185,000. State Street Corp boosted its stake in Coherus BioSciences by 26.8% in the second quarter. State Street Corp now owns 1,416,572 shares of the biotechnology company’s stock valued at $20,329,000 after buying an additional 298,986 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its stake in Coherus BioSciences by 14.6% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 23,362 shares of the biotechnology company’s stock valued at $334,000 after buying an additional 2,979 shares during the period. Hedge funds and other institutional investors own 72.41% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/23/coherus-biosciences-inc-chrs-trading-22-1-higher.html.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.